With 5-year follow-up in a real-world population, frontline pembrolizumab monotherapy continues to demonstrate long-term effectiveness, with survival outcomes consistent with those of pivotal clinical trials, for treating patients with advanced NSCLC with PD-L1 expression of ≥ 50% and no EGFR, ALK, or ROS1 genomic alteration.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- clinical trial
- combination therapy
- open label
- tyrosine kinase
- randomized controlled trial
- systematic review
- dna damage
- phase ii
- reactive oxygen species
- brain metastases
- dna methylation
- study protocol
- gene expression
- skeletal muscle
- insulin resistance
- weight loss
- genome wide